March 16, 2017
Genetic tests are being used more commonly in the diagnosis of many types of cancer. However, there currently isn’t a highly accurate test that can identify men with aggressive forms of prostate cancer, making it more difficult to choose the most appropriate course of treatment.
January 10, 2017
Prostate cancer is the most common cancer in Canadian men, but there is still no one-size-fits-all strategy for treating the disease. Currently it is difficult to choose exactly the right type and amount of treatment for each individual because it is hard to accurately assess how aggressive the cancer is. Researchers are now a step closer to bringing a powerful new prognostic tool into clinical use.
January 9, 2017
A team of researchers and clinician-scientists from across Canada have discovered a signature of 41 mutations that are common in prostate cancer and will help to prevent patients with non-aggressive disease from being overtreated. Dr. Paul Boutros, a Principal Investigator in OICR’s Informatics and Bio-computing Program and Co-Lead of the Canadian Prostate Cancer Genome Network (CPC-GENE), answered a few questions about how the signature was developed and its potential impact on patients.
January 9, 2017
Findings published in renowned journal Nature
January 9, 2017 – TORONTO, ON – The Canadian Prostate Cancer Genome Network (CPC-GENE) has published findings from the world’s most comprehensive genetic analysis of prostate cancer tumours in the journal Nature. Led by Drs. Robert Bristow of the Princess Margaret Cancer Centre and Paul Boutros of the Ontario Institute for Cancer Research, CPC-GENE has uncovered the full set of mutations that can occur in the most common cancer in men. By fully cataloging these mutations, the CPC-GENE team was able to create a new signature that predicts at an early stage whether a prostate cancer tumour will become aggressive or not, allowing for personalized treatment.
January 5, 2017
Are vasectomies safe? Some recent studies have found a link between vasectomies and the development of prostate cancer later in life. But new research using Ontario health data has challenged these studies and shown conclusively that there is no link, giving new peace of mind to those men who have undergone or are considering undergoing the procedure.
December 6, 2016
Dr. Ahmed Aman, Principal Research Scientist and Group Leader, Analytical Chemistry and ADME in OICR’s Drug Discovery Program, recently demonstrated that his commitment to cancer research goes beyond his work in the lab. For the sixth straight year Aman participated in Movember by growing a moustache to raised funds and awareness for men’s health issues, including prostate cancer. This year Aman exceeded his fundraising goal of $500 by collecting $770 in donations and has now raised $3,445 since beginning in 2011.
More information about Movember can be found here: https://ca.movember.com/
Tags: Prostate cancer
November 9, 2016
Men newly diagnosed with prostate cancer face a difficult dilemma: either wait and see how the growth develops and whether it is aggressive, or treat it fully right away and risk the many long-term side effects of treatment. Dr. Tamara Jamaspishvili is a young researcher at Queen’s University in Kingston who is working to change that.
October 19, 2016
Prostate cancer is the most common cancer in Canadian men and while it has been the focus of extensive research, an estimated 4,000 Canadians die of the disease each year. That is why six years ago Dr. Paul Boutros and Dr. Rob Bristow set out to sequence the normal and diseased tissue of 350 patients and learn from a clinical perspective how genomic information can be used to guide better treatment.
October 12, 2016
Prostate cancer is a complex disease. In a clinical setting it can be hard for doctors to accurately predict outcomes for prostate cancer patients, especially for those deemed to be at an intermediate risk of recurrence. With intermediate risk cancers, unlike those that are high or low risk, it is unclear how the cancer will develop. This makes it difficult to choose exactly the right therapy and avoid unnecessary treatments and their associated side effects.
September 15, 2016
Dr. Paul Boutros, Principal Investigator in Informatics and Bio-computing at OICR, spoke to our partners at Prostate Cancer Canada/Movember Canada about the role of genomics and informatics in prostate cancer research. Boutros also spoke about the CPC-GENE project – the largest study of prostate cancer genomics in the world.
August 16, 2016
Noncoding RNA may play a bigger role in driving prostate cancer development and progression that previously thought.
On Monday the University Health Network’s Princess Margaret Cancer Centre announced that prostate cancer researchers, funded in part by OICR, have pinpointed the key regulatory role of 45 noncoding genes in the development and progression of prostate cancer. The research was published in Nature Genetics.
July 4, 2016
OICR congratulates Drs. Mark Levine, Eduardo L. Franco and Gerald Batist, new recipients of the Order of Canada
Three cancer researchers were invested into the Order of Canada over the weekend, including Dr. Mark Levine, C.M., who was honoured for his contributions as an oncologist, researcher and clinician and because he has developed several new treatments for cancer patients that are now used as standard of practice in Canada.
Levine is Director of the Ontario Clinical Oncology Group (OCOG), Chair of the Department of Oncology for the Michael G. DeGroote School of Medicine at McMaster University and a medical oncologist at Juravinski Cancer Centre at Hamilton Health Sciences.
For more information on OICR's research, careers, events and education, visit our corporate website: OICR.ON.CA